Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately. “We ar...
This is the Company’s second year to be included as one of the Top 100 Companies in Houston Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced it has bee...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test. DecisionDx-SCC is...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that Derek Maetzold, president and chief executive officer, is scheduled to present a company overview at the Baird 2021 ...
New 23,700- square-foot facility houses the Company’s Houston-based employees and supports remote corporate employees Ribbon-cutting ceremony to be held May 25 Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized g...
The ASA Castle Biosciences Research Grant Melanoma was awarded to Joel Sunshine, M.D., Ph.D., Johns Hopkins School of Medicine Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions...
Article in Journal of Drugs in Dermatology provides a framework for integrating DecisionDx-SCC into patient care Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today an...
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced that management will participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit, May 26, 2021. Derek Maetzol...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Castle Biosciences, Inc. 2021 Q1 - Results - Earnings Call Presentation
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Tiffany Olson has been appointed to its board of directors, effective immediately. “We are pleased...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...